Literature DB >> 6703672

Comparative pharmacokinetics of apalcillin and piperacillin.

H Lode, A Elvers, P Koeppe, K Borner.   

Abstract

The pharmacokinetics of apalcillin and piperacillin, each administered intravenously as a single 2-g dose, were compared in 10 volunteers in a randomized study of crossover design using bioassay and high-pressure liquid chromatographic procedures. The concentrations of both penicillins in serum were determined over a period of 12 h and in urine over 24 h. Concentrations of apalcillin and piperacillin at the end of the 15-min infusion were similar; however, at 8 h, concentrations of piperacillin were below measurable levels, whereas concentrations of apalcillin were still measurable at 10 h. Pharmacokinetic parameters were calculated according to a two-compartment open model. The area under the curve and the half-life for apalcillin were larger than for piperacillin. On the other hand, renal clearance of piperacillin was substantially greater than that of apalcillin. Of the apalcillin excreted via the kidneys, approximately one-fifth was eliminated as two microbiologically inactive penicilloic acid derivatives. The nonrenal clearance of apalcillin was 79% of total clearance. Binding of apalcillin to serum protein was almost twice that of piperacillin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703672      PMCID: PMC185444          DOI: 10.1128/AAC.25.1.105

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates.

Authors:  H Noguchi; M Kubo; S Kurashige; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

Review 3.  Penicillins.

Authors:  T Bergan
Journal:  Antibiot Chemother (1971)       Date:  1978

4.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

5.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

6.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

7.  Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

9.  PC-904, a new semisynthetic penicillin.

Authors:  G P Bodey; S Weaver; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

10.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

View more
  8 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers.

Authors:  A L Barry; R N Jones; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

6.  Comparative in vitro activities of apalcillin and piperacillin against gram-negative bacilli.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

7.  Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

Authors:  J D Allan; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  The pharmacokinetics of the interstitial space in humans.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2003-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.